Engitix Ltd is a company that formed as a spin-off from the research carried out at the Institute for Liver and Digestive Health in the Division of Medicine at the University College London (UCL) . This company has been leading the development of extracellular matrix that mimics different cell types (specifically liver, intestine, and pancreatic cell structure) in order to better understand how diseases affect these areas of the body and how different medications can help fight them .
The company focuses on fibrosis and solid tumours, using the developed extracellular matrix as a way to see the structure of the cells and how it reacts with certain diseases and medications . The team is collaborating with several big biotech and pharmaceutical companies with the home that they will be able to find a solution for the diseases that they study .
Last week this company announced that it had closed £5 million in Series A financing. With this influx of money, Engitix will be able to increase the size of its Research and Development team as well as expanding with an office in Boston, USA. This means that they will be able to increase the amount of work within the laboratory as well as their interactions with organisations specialising in drug development around the world.